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Purpose: The objective of present study is to determine serum levels and
placental distribution of two interacting proteins calcyclin and heat shock
protein 90 in preeclampsia.
Experimental design: Maternal serum levels of calcyclin and heat shock
protein 90 are compared throughout pregnancy from the ﬁrst trimester till
term among women with preeclampsia (n = 43) and age-matched
normotensive pregnant controls (n = 46). A serum-based 2D LC-MS assay
using Parallel Reaction Monitoring is applied to quantify both calcyclin and
heat shock protein 90.
Results: Serum levels of calcyclin are signiﬁcantly lower in patients with
preeclampsia in the second trimester of pregnancy as compared to controls
(p < 0.05). Serum levels of heat shock protein 90 are signiﬁcantly higher in
patients with preeclampsia in the third trimester as compared to controls
(p < 0.001).
Conclusion and clinical relevance: Both interacting proteins calcyclin and
heat shock protein 90 are notably changed in preeclamptic patients compared
to controls. Calcyclin is already decreased before the onset of preeclampsia in
the second trimester and HSP90 is strongly increased in the third trimester.
This suggests that these proteins may play a role in the pathogenesis of
preeclampsia and ought to be investigated in large cohort studies as
molecular biomarkers.
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1. Introduction
Preeclampsia (PE) is a pregnancy-speciﬁc
multi-organ disorder that is diagnosed by
new-onset hypertension and proteinuria
after 20 weeks of gestation.[1] It aﬀects
2–8% of all pregnancies and is one of
the leading causes of maternal mortal-
ity worldwide.[1,2] Also, perinatal mortal-
ity is ﬁve times higher in women with
PE.[2] The exact cause of PE remains un-
known but most likely is the result of
an abnormal placentation during the ﬁrst
trimester of pregnancy usually observed
in early-onset PE. During normal preg-
nancies, cytotrophoblast cells promote
arteriolar dilation by invading the uter-
ine spiral arteries. In PE, cytotrophoblast
cells do not invade the spiral arteries ad-
equately, resulting in reduced placental
blood ﬂow leading to excessive placental
oxidative stress.[3] Signs of pending PE
may be expected to be notable early in
pregnancy before the onset of the clini-
cal disease. Studying serummarkersmay
lead to an understanding of the pathogen-
esis of PE at a protein level. The lattermay
contribute to better screening, monitoring, and possible preven-
tion of this disorder.
Previously, we reported signiﬁcantly discriminating peptide
patterns between trophoblast and stroma cells by laser cap-
ture microdissection (LCM).[4] We also demonstrated by im-
munohistochemistry that S100A6 was signiﬁcantly more abun-
dant in placentas of preeclamptic women as compared to
controls.[5] By multiple reaction monitoring (also known as
SRM) we showed signiﬁcantly elevated levels of S100A6 in
formalin-ﬁxed paraﬃn-embedded (FFPE) preeclamptic placen-
tas compared to controls by LCM.[6] Concentrations of serum
S100A6 in healthy nonpregnant persons were known to be
low (2–8 ng mL−1).[7] S100 proteins, including S100A6,
interact with the tetratricopeptide repeat (TPR) domains of
the HSP70 and HSP90 (HSP70/HSP90)-organizing protein
(Hop) in a Ca2+-dependent manner. After interacting with
S100A6, HSP70, and HSP90 dissociates from Hop-HSP70
and Hop-HSP90 complex and blocks binding to other partner
proteins.[8]
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Based on our previous research on placental tissue and on
the hypothesis, that S100A6 activates HSP90 via the HOP pro-
tein as a result of oxidative stress, it is suggested that HSP90
might also play a role in the pathophysiology of PE. For this pur-
pose, a cross-sectional study was performed with hard to acquire
set of maternal serum samples transversally collected during the
ﬁrst, second, and third trimesters of pregnancy. We investigated
whether these two proteins behave diﬀerently in patients with PE
as compared to pregnant normotensive controls. A serum-based
2D LC/MS PRM assay[9] was used to quantify both proteins. In
addition, we developed a double immunoﬂuorescence staining
with antibodies against S100A6 and HSP90 to show that both
proteins S100A6 andHSP90 are present in trophoblast cells.
2. Experimental Section
2.1. Study Design
A case-control study was conducted at the Department of Ob-
stetrics and Gynecology of the Erasmus MC, Rotterdam, the
Netherlands. Serum samples from two diﬀerent studies were
used: a nested case-control study embedded in the Rotterdam
Periconceptional Cohort (Predict study),[10] a prospective tertiary
hospital-based study, and the Lepra Study,[11] a retrospective ter-
tiary hospital-based case-control study focused on brain involve-
ment during PE. Both studies were approved by the local Medical
Ethical and Institutional Review Board of Erasmus MC (MEC-
2004-227 and MEC 2007–086, respectively). At admission, par-
ticipants gave written informed consent for participation. Serum
samples were available of 43 patients with PE, consisting of 20
early-onset and 23 late-onset PE, and 46 normotensive controls.
Sixty-three percent of the samples were collected in the ﬁrst
trimester (<14 weeks), 17 percent in the second trimester (14–
27 weeks) and 20 percent in the third trimester (28 weeks) of
pregnancy. These percentages did not diﬀer between cases and
controls. Cases and controls were matched for maternal age, ge-
ographic origin, parity and gestational age at sampling. PE was
deﬁned as systolic blood pressure140mmHgor diastolic blood
pressure 90 mm Hg on at least two occasions 4 h apart af-
ter 20 weeks of gestation with proteinuria (protein/creatinine ra-
tio of  30 mg mmol−1) following the ISSHP guidelines. Clini-
cal data were obtained from questionnaires and medical records.
An independent set consisting of ten placental tissues that were
provided by the department of Pathology, Erasmus MC, were
used for immunoﬂuorescence studies. Five were obtained from
women who experienced early-onset PE and ﬁve from women
with spontaneous preterm delivery without hypertension.
2.2. Sample Preparation by SCX Chromatography
Seven microliters of each serum sample was diluted 47 times
in 0.01% RapiGest (Waters, Milford, MA) dissolved in 50 mm
ammonium bicarbonate, reduced using 15 mm DTT followed
by alkylation using 15 mm iodoacetamide (IA) and subsequently
enzymatically digested by adding 30 μL trypsin (100 μg mL−1
dissolved in 3 mm Tris-HCl pH 8.8) (Gold, Mass Spectrom-
etry Grade, Promega, Madison, WI) at 37 °C overnight. The
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enzymatic reaction was stopped by adding 50% of formic acid
(FA) to reach a ﬁnal concentration of 0.5–1.0% FA. All digested
sera were spiked with 40 fmol of both S100A6 and HSP90 sta-
ble isotope-labeled (SIL) peptides (Thermo Fisher Scientiﬁc, Bre-
men, Germany; purity of > 97% as stated by the manufacturer
(Ultimate-grade)), followed by desalting by Solid Phase Extraction
(Discovery DSC-18 SPE 96-well Plate, Sigma-Aldrich, the Nether-
lands). Subsequently digested samples were fractionated by SCX
chromatography to measure relatively low levels (ng mL−1) of
S100A6 and HSP90 in sera from PE patients. All samples were
oﬀ-line fractionated with a Luna 5 μm, 150 × 2 mm SCX col-
umn (Phenomenex, Torrance, CA) that was connected to a nano-
LC system (Thermo Fisher Scientiﬁc, Germering, Germany) us-
ing the following conditions: buﬀer A (14 mm KH2PO4, 24 mm
H3PO4, pH 2.5, adjusted with 37% w/wHCl) in 25% v/v acetoni-
trile (HPLC grade; Biosolve, Valkenswaard, the Netherlands) in
Milli-Q water; buﬀer B (buﬀer A containing 350 mm KCl); linear
gradient from 100% buﬀer A to 40% buﬀer B in 40min, followed
by a wash with 100% buﬀer B until 45 min at a ﬂow rate of 200
μLmin−1 and equilibration of the column in buﬀer A for 17min.
All chemicals used for SCX fractionation were purchased from
Sigma-Aldrich (St Louis, MO). As shown previously,[9] 50 μL
fractions (180 fractions in total for each serum sample) were
automatically collected in 384-well plates (VWR, Amsterdam,
the Netherlands) and sealed with an adhesive aluminum foil
(VWR, Amsterdam, the Netherlands). Fractions were dried down
in SpeedVac concentrator (RVT4104, Scientiﬁc Savant, San Jose,
CA) and subsequently stored at −20 °C until further analysis.
Only fractions containing the two peptides (on average eight)
were reconstituted in 0.1% FA prior PRM measurements.
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2.3. PRM in Serum and Placental Tissue
A PRM assay was developed for quantitative measurements of
S100A6 andHSP90 levels in serumusing SIL peptides serving as
internal standards, that is, LQDAEIAR (13C615N4) for S100A6 and
YIDQEELNK (13C615N2) related to both isoforms HSP90α and
HSP90β. HSP90β was not analyzed, because it is known from
literature that very low levels (1–2 ng mL−1) of HSP90β were
usually measured in serum.[12]
For S100A6, a relatively low molecular weight protein
(10 kDa) only the single signature peptide LQDAEIAR was
used because other tryptic S100A6 peptides contain amino
acids that are prone to oxidation (methionine, cysteine), acety-
lation, phosphorylation or are too long, that is, more than
20 amino-acids. The single signature peptide YIDQEELNK
was used for HSP90 measurements, because almost identi-
cal results were obtained for another HSP90 peptide DQ-
VANSAFVER as explained in our previous paper.[9] In this study,
an agreement between ELISA and PRM results for HSP90 was
shown.
PRM signals for S100A6were recorded for doubly-charged en-
dogenous and SIL peptide LQDAEIAR precursor ions with m/z
of 458.25 and m/z 463.25, respectively. For HSP90, m/z 576.28
and m/z 580.29 were taken for YIDQEELNK, respectively. PRM
measurements were carried out on a nano-LC system (Thermo
Fisher Scientiﬁc, Germering, Germany) online coupled to an Or-
bitrap Fusion mass spectrometer (Thermo Fisher Scientiﬁc, San
Jose, CA, US). Three microliters of each SCX-fractionated sam-
ple were loaded on to a trap column (PepMap C18, 300 μm ID ×
5 mm length, 5 μm particle size, 100 A˚ pore size; Thermo Fisher
Scientiﬁc), washed and desalted for 5min using 0.1% TFA in wa-
ter as loading solvent. The trap column was then switched in-line
with the analytical column (PepMap C18, 75 μm ID × 250 mm,
2 μm particle and 100 A˚ pore size, Thermo Fisher Scientiﬁc).
Peptides were eluted with a binary gradient from 12% to 25%
solvent B for 14.7 min, where solvent A consisted of 0.1% FA in
water, and solvent B consisted of 80% acetonitrile and 0.08% FA
in water. The column ﬂow rate was set to 250 nL min−1 and oven
temperature to 40 °C. All LC solvents were UHPLC grade and
purchased at Biosolve, Valkenswaard, the Netherlands. For elec-
trospray ionization, nano ESI emitters (New Objective, Woburn,
MA) were used and a spray voltage of 1.8 kV was applied. For
PRM of the doubly-charged precursor ions of LQDAEIAR and
YIDQEELNK (endogenous and SIL), the targeted MS/MS mode
set up as follows was used: isolation width 1.4 Da, HCD fragmen-
tation at a normalized collision energy of 25%, ion injection time
was set to 512 ms (by setting the AGC target to 500 000 ions),
Orbitrap resolution of 240 000. Selection of the precursor ions
was time scheduled and each duty cycle consisted of two targeted
MS/MS scans (endogenous and SIL form of a peptide) yielding a
scan rate of approximately 0.83 Hz. Fluoranthene (202.0777 Da)
was infused as lock mass (Easy IC option active).
The PRM data have been deposited to the ProteomeXchange
Consortium via the PRIDE[13] partner repository with the dataset
identiﬁer PXD009025.
Placental abundances of S100A6 and HSP90; whole tissue
lysates collected from placentas of six preeclamptic patients,
ﬁve age-matched preterm controls and four term controls were
determined. Collected tissue pieces were collected in 200 μL
0.1% Rapigest SF detergent, sonicated for 3 min using a horn
soniﬁer bath (Ultrasonic Disruptor Soniﬁer II, Bransons Utra-
sonics, Danbury, CT, USA) at 85% amplitude and heated for 5
min at 99 °C for protein denaturation. Fifty out of the 200 μL tis-
sue lysates were each spiked with 1 fmol of S100A6 and HSP90
SIL peptides prior to enzymatic digestion. Samples were digested
by adding 2 μg trypsin at 37 °C overnight. PRM measurements
were carried out on an Orbitrap Lumos (Thermo Fisher Scien-
tiﬁc, Germering, Germany) instrument as described above with
an adjustment of the gradient condition (from 4% to 38% solvent
B for 30 min) to quantify protein levels of HSP90, and S100A6.
Measured data were normalized based on UV data obtained dur-
ing online LC-MS measurements of the tissue taken for each
sample.
2.4. Data Analysis
The PRM signals were integrated and analyzed using Skyline.[14]
The linearity, LOD and LOQ of the assay were determined
for S100A6 and HSP90 peptides according to our previous
work[9] by spiking ﬁve diﬀerent concentrations in triplicate
into an SCX-separated serum digest. For each protein, the lin-
ear regression data including reproducibility of the serial di-
lutions of SIL peptide standards (expressed as %CV), LOD
and LOQ are represented in Supporting Information, Excel
data 1.
The SCX-fractionated serum digests were measured in a sin-
gle run whereas ratios between endogenous and SIL peptides of
S100A6 and HSP90 were calculated to determine the concentra-
tions. Only fractions containing the highest S100A6 or HSP90
concentration were considered for further analysis. Statistical dif-
ferences between serum levels of S100A6 andHSP90 in the total
PE group, in the subgroups of early- and late-onset, and control
group during the ﬁrst, second, and third trimesters were calcu-
lated with an unpaired t-test. A probability below 0.05 was con-
sidered to be signiﬁcant. Serum levels were tested for normal-
ity using Kolmogorov–Smirnoﬀ and Shapiro–Wilk tests. Natural
log (ln)-transformed values were used for statistical testing if data
were not normally distributed. To evaluate the repeatability and
reproducibility of the PRM assay, for both peptides three tech-
nical (three PRM measurements of an identical sample (qual-
ity control) throughout the assay run) and three methodological
(three independently prepared replicates of an SCX-fractionated
serum sample) replicates weremeasured and CVs as percentages
calculated, respectively.
For statistical analysis of clinical characteristics independent
students’ t-tests (normal distributed data) or Mann–Whitney
U tests (non-normal distributed data) were used for continuous
variables and Chi-square tests or Fisher’s exact tests were used
for categorical variables.
Unsupervised hierarchical cluster analysis was performed
to illustrate whether the proteins S100A6 and HSP90
were correlated with various metadata (Supporting Infor-
mation, Excel data 2) of the investigated subjects. The
following parameters were set using PermutMatrix 1.9.3.
(http://www.atgc-montpellier.fr/permutmatrix): Pearson dis-
tance for dissimilarity, Wards’ method, as a cluster method and
Bipolarization seriation.[15,16]
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2.5. Double Immunoﬂuorescence Microscopy
FFPE placental material from an independent set consisting of
ﬁve preeclamptic women and ﬁve age-matched preterm deliv-
ered controls (26–32 weeks; used for routine procedures accord-
ing to our department of Pathology and "Code of Conduct for
Responsible use" by the FEDERA, http://www.federa.org) were
used for immunoﬂuorescence with antibodies against S100A6
and HSP90. Tissues were cut in 4 μm sections and routinely
processed. Immunoﬂuorescence assays were performed on a
VENTANA BenchMark Discovery automated staining instru-
ment (Ventana Medical Systems), using VENTANA reagents
except as noted, according to the manufacturer’s instructions.
Slides were de-paraﬃnized using EZ Prep solution (cat # 950–
102) for 16 min at 72 °C. Epitope retrieval was accomplished
with CC1 solution (cat # 950–224) at high temperature 97 °C
for a period of time 36 min. Mouse-anti-S100A6 (clone CACY-
100, Sigma-Aldrich), was manually applied for 1 h and 4 min
at 37 °C followed by second antibody UMAP anti-mouse con-
jugated with horseradish peroxidase for 12 min followed by
0.01% H2O2 and Red 610-tyramide detection (cat # 760-245).
Next, antibody denature step was done at 97 °C for 12 min with
CC2 solution (cat # 950-223). Subsequently mouse-anti-HSP90
(clone D7a, Abcam) was manually applied and incubated for
40 min at 37 °C. Then conjugated by second antibody UMAP
anti-mouse with horseradish peroxidase for 12 min followed
by the application of 0.01% H2O2 and FAM-tyramide detection
(cat #760-243). The slides were counterstained with DAPI Vec-
tashield (Vector Laboratories, Burlingame, CA) and imaged us-
ing the LSM 700 (Carl Zeiss, Germany) laser scanning confocal
microscope.
3. Results
3.1. Clinical Characteristics of Study Groups
Clinical characteristics (Table 1) did not statistically diﬀer be-
tween the study groups, except for "chronic hypertension"
and "PE in a previous pregnancy," which was present expect-
edly more often in the cases. Women with PE had higher
blood pressure and lower birth weight of the neonate. Women
with PE reported more often complaints of headache, vi-
sual disturbances, upper abdominal pain, nausea, and general
discomfort.
3.2. Serum S100A6 and HSP90 Levels
Table 2 shows the results of comparisons between patients with
PE and controls at diﬀerent gestational ages for S100A6 and
HSP90 measured by PRM. Serum levels were not normally dis-
tributed and for this reason the ln-transformed values were used
for statistical testing. A complete overview of S100A6 andHSP90
levels measured in PE and control is illustrated in Figure 1 by
plotting each protein level against the trimester group. Serum
levels of S100A6were overall lower in patients with PE compared
to controls (Table 2, 59.8 ng mL−1 vs 0.6 ng mL−1, p < 0.05)
analyzed for all three trimesters together. When analyzing the
trimesters separately, it was observed that during the second
trimester S100A6 was signiﬁcantly lower in patients with PE
(Table 2, 41.7 ng mL−1 versus 75.6 ng mL−1, p < 0.05). In the
other two trimesters, an increasing not signiﬁcant trend was
observed.
Serum levels ofHSP90 were overall signiﬁcantly higher in pa-
tients with PE compared to controls (Table 2, 103.3 ng mL−1 vs
93.7 ng mL−1, p < 0.05). When analyzing the trimesters sep-
arately HSP90 was signiﬁcantly higher in serum of cases only
in the third trimester (Table 2, 194.2 ng mL−1 vs 62.6 ng mL−1,
p < 0.001).
The LOD and LOQ for S100A6 that was based on peptide LQ-
DAEIAR was 0.3 ng mL−1 and 0.8 ng mL−1, respectively. The
LOD and LOQ forHSP90 was 2.8 and 8.6 ng mL−1, respectively.
The CV for repeatability and reproducibility calculated for the
S100A6 peptide LQDAEIAR was 3.6% and 2.0%, respectively. In
the case ofHSP90, the CV was 2.1% and 6.8% for YIDQEELNK,
respectively.
Sensitivity analysis of the S100A6 and HSP90 serum levels
individually analyzed per trimester and for all three trimesters
together did not reveal any signiﬁcant diﬀerence between
early- and late-onset PE. Furthermore, we investigated by un-
supervised hierarchical clustering that various parameters were
correlated with S100A6 and HSP90. The patient and con-
trol group were separated completely (Figure S1, Supporting
Information).
3.3. The Abundances of S100A6 and HSP90 in Placental Tissue
Measured by PRM
Results showed that S100A6 (Figure S2A, Supporting Informa-
tion) was signiﬁcantly diﬀerent between preeclamptics and term
controls (p = 0.0381). Comparing the preeclampsia group with
the preterm control group was not signiﬁcant (p = 0.7619).
For HSP90 (Figure S2B, Supporting Information), we did not
ﬁnd signiﬁcant diﬀerences between preeclamptics and term con-
trols (p = 0.9307). Comparing the preeclampsia group with the
preterm control group was also not signiﬁcant (p = 0.0519)
(borderline).
3.4. Colocalization of S100A6 and HSP90 in Placentas by
Immunoﬂuorescence Staining
Using immunoﬂuorescence staining, it was observed that
S100A6 and HSP90 were partially colocalized in cytoplasm
of trophoblast cells from placental tissue of preeclamptic
patients (n = 5) and preterm matched controls (n = 5).
Figure 2 is an example of immunoﬂuorescence trophoblast
staining for S100A6 and HSP90 in placenta of a PE case
and age-matched preterm control. The immunoﬂuorescence re-
sults showed that often overlap was observed between S100A6
and HSP90 in the trophoblast cells. At the stromal part of
the chorion villi, no staining or at least no overlap was
observed.
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Table 1. Clinical characteristics.
General characteristics a PE (n = 43) Normotensive control (n = 46) p-valueg
Maternal age, years 33 (5) 33 (5) 0.820
Geographical origin 0.800
Western 29 (67.4%) 28 (62.2%)
Non-Western 14 (32.6%) 17 (37.8%)
Study cohort
Predict study 30 (70%) 22 (48%)
Lepra study 13 (30%) 24 (52%)
Index pregnancy
Nulliparous 23 (53.5%) 24 (52.2%) 0.901
Preconception BMI, kg m−2 27 (5) 25 (6) 0.237
Smoking (during pregnancy) 3 (7.5%) 0 (0%) 0.215
Highest systolic blood pressure, mmHg 155 (17) 126 (10) <0.001
Highest diastolic blood pressure, mmHg 100 (9) 77 (6) <0.001
Proteinuria (gram per 24 h) 0.54 NA
Protein/creatinine-ratio 63 NA
Gestational diabetes 1 (2.3%) 2 (4.3%) 1.000
Twin pregnancy 3 (7%) 3 (6.5%) 1.000
Serum sampling
Gestational age in weeks 12 (6–31) 10 (6–31) 0.608
Gestational age in days 87 (46–117) 75 (45–117) 0.464
Trimester comparison 0.982
Number of samples
First trimester 27 (62.8%) 29 (63.0%)
Second trimester 7 (16.3%) 8 (17.4%)
Third trimester 9 (20.9%) 9 (19.6%)
Medical history
Chronic hypertension 13 (30.2%) 0 (0%) <0.001
Insulin Dependent Diabetes Mellitus 1 (2.3%) 1 (2.2%) 1.000
Obstetric history
Recurrent miscarriages 0 (0.0%) 5 (10.9) 0.056
PE in previous pregnancy 13 (30.2%) 2 (4.3%) <0.05
Previous Caesarean delivery 8 (18.6%) 10 (21.7%) 0.713
Phenotypes preeclampsia
HELLP 13 (30.2%) NA NA
Early-onset PE b 20 (8d, 4e, 8f) (47.6%) NA NA
Late-onset PE b 23 (19d, 3e, 1f) (52.4%) NA NA
Severe PE b 21 (50%) NA NA
Clinical symptoms
Headache 21 (51.2%) 2 (4.3%) <0.001
Visual complaints 10 (24.4%) 2 (4.3%) <0.05
Upper abdominal pain 15 (36.6%) 1 (2.2%) <0.001
Nausea 11 (26.8%) 2 (4.3%) <0.05
General discomfort 6 (14.6%) 0 (0%) <0.05
Dyspnea 3 (7.3%) 1 (2.2%) 0.339
Neonatal characteristics c
Birth weight, gram 2335 (1410–2845) 3310 (2940–3675) <0.001
Birth weight < 10th percentile 9 (20%) 2 (4.2%) <0.05
Male gender 25 (54.3%) 20 (41.7%) 0.219
a)Data are presented as n (%), mean with standard deviation (SD) or median with range. b)These deﬁnitions are according to the ISSHP guidelines, see reference.[32] c)Due
to ﬁve twin pregnancies with living children (n = 94). d)number of samples in the ﬁrst trimester, e)second trimester, f)third trimester. g)For comparisons between groups,
independent students’ t-tests, Mann–Whitney U tests, Chi-square tests and Fisher’s exact tests were used. NA = not applicable.
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Table 2. S100A6 and HSP90 serum levels measured by PRM of women with PE and pregnant normotensive controls from the ﬁrst (1st), second (2nd),
and third (3rd) trimesters of pregnancy. Statistical comparisons were made by using an unpaired t-test. Serum levels were not normally distributed and
therefore an ln-transformation was used to normalize the data. A probability value below 0.05 was considered to be signiﬁcant.
S100A6 trimester PE (n = 43) concentration
in ng mL−1 (median; IQR)
CO (n = 46) concentration in
ng mL−1 (median; IQR)
p-value
1st (n = 56) 59.3 (34.0–68.6) 63.2 (47.3–92.0) NS
2nd (n = 15) 41.7 (36.6–47.2) 75.6 (54.5–143.4) <0.05
3rd (n = 18) 113.2 (68.7–191.2) 171.8 (63.4–781.7) NS
all (n = 89) 59.8 (36.8–78.0) 80.6 (49.7–102.2) <0.05
HSP90 trimester
1st (n = 56) 100.1 (80.8–118.9) 96.7 (76.9–140.7) NS
2nd (n = 15) 91.9 (66.0–101.3) 105.4 (63.9–132.5) NS
3rd (n = 18) 194.2 (116.8–412.4) 62.6 (53.7–79.0 <0.001
all (n = 89) 103.3 (83.0–157.6) 93.7 (65.0–125.8) <0.05
PE = preeclampsia; CO = pregnant normotensive control; IQR = interquartile range; NS = not signiﬁcant.
Figure 1. Serum levels of A) S100A6 and B) HSP90 were measured (for
individual concentrations per trimester, see Table 2) for each PE (red) and
control (blue) group obtained from the ﬁrst, second, and third trimesters.
In the second trimester S100A6was signiﬁcantly lower in serumof patients
with PE compared to controls. Serum levels of HSP90 were signiﬁcantly
elevated in the third trimester.
4. Discussion
Serum S100A6 and HSP90 levels of matched cases and con-
trols could be measured in a sensitive and high-quality man-
ner. PRM results of S100A6, based on endogenous peptide LQ-
DAEIAR, showed a signiﬁcantly lower serum concentration in
the second trimester of pregnancy in women with PE compared
to normotensive controls. PRM results of HSP90, based on en-
dogenous peptide YIDQEELNK, showed a signiﬁcantly higher
serum concentration in third trimester of pregnant women with
PE compared to normotensive controls, but not in the ﬁrst and
second trimesters.
The ﬁnding that a signiﬁcant decrease was observed of S100A6
levels in the second trimester of PE patients was remarkable and
suggests that S100A6 is involved in the pathophysiology of PE as
was already observed previously in placental tissue.[5] In placental
tissue, we observed that S100A6was higher abundant in patients
with PE. However, the expression in serum of this protein may
be more complex and diﬀerent from the expression in placen-
tal tissue. So, the idea that elevated levels in tissue would also
automatically result in higher levels in serum could be not true
because S100A6 might have a diﬀerent clearance rate from the
blood or have a diﬀerent degradation process in serum or in the
originating tissue. The precise biological or cellular function of
S100A6 remains unclear.[17] It is known that S100A6 plays a role
in cellular stress response; there is an upregulation of S100A6
in cells which are exposed to oxidative stress. Placental oxida-
tive stress is known to precede the development of PE.[18] Pla-
centas from preeclamptic women have reduced antioxidant ca-
pacity showing lower levels of antioxidants in blood.[18] S100A6
is a member of the S100 subfamily which consists of two EF-
hand calcium binding motifs that act as a signal-transducer in
intracellular processes.[19] Intracellularly, these proteins function
as Ca2+-signaling and Ca2+-buﬀering proteins. Calcium induces
a conformational change of the protein structure. By this change
an interaction site of S100 proteins with their target proteins is
exposed.[20] Extracellularly, the S100 proteins (including S100A6)
are known to be interacting with the Receptor for Advanced Gly-
cation End products, known as RAGE-receptors.[21] These pro-
teins have a cytokine-like function and could for example act
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Figure 2. Example of double immunoﬂuorescence staining. It shows trophoblast staining for both proteins S100A6 andHSP90 in a A) preeclamptic and
B) age-matched preterm delivered control (placental tissue at 40×magniﬁcation. For S100A6 (red) both cytoplasm and nucleus (partially) of trophoblast
cells were positive, while for HSP90 (green) only cytoplasm was stained of trophoblast cells. Colocalization of both proteins is indicated with a merged
color. Red blood cells showed autoﬂuorescence for S100A6. For nuclear counterstain the slides were stained with DAPI.
as chemotactic molecules during inﬂammation. Recent evidence
suggests RAGE to play a separate role in inﬂammatory and vas-
cular autoimmune diseases. RAGE proteins are expressed in sev-
eral cells in vasculature tissue such as endothelial cells, inﬁltrat-
ing inﬂammatory cells, cardiomyocytes, and ﬁbroblasts.[22] Pla-
cental cells from PE patients were found to have increased levels
of RAGE proteins[23] suggesting an involvement of S100A6 pro-
tein in the pathophysiology of PE.
Because of the limited power of the study it was not possible
to establish signiﬁcant diﬀerences between early- and late-onset
PE per trimester. Most likely HSP90 increases also as a conse-
quence of secondary mechanisms (e.g., inﬂammation) and not
necessarily as a cause or as an early event that leads to the
clinical onset of PE. S100A6 and HSP90 are both expressed in
trophoblast cells as conﬁrmed by double immunoﬂuorescence
staining (Figure 2). S100A6 is partially located in nuclei and
cytoplasm while HSP90 was only found in cytoplasm of tro-
phoblast cells although these proteins have also been found
outside cells.[24] A similar expression is described in “The Hu-
man Protein Atlas” (http://www.proteinatlas.org). S100A6 inter-
acts with heat shock proteins such as HSP70/HSP90 complexes
and may promote endothelial cell-cycle progression by this in-
teraction. HSP90 is the most abundant heat shock protein in
eukaryotic cells. It consists of two isoforms with largely similar
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functions known as HSP90α and HSP90β. In this study, we
made no distinction between these two protein isoforms.HSP90
is a chaperone protein that plays a role in the folding, stabiliza-
tion, and activation of denatured and synthesized proteins which
are involved in various cellular processes.HSP90 plays an impor-
tant role in stress responses and maintaining cellular homeosta-
sis.HSP90 proteins interact with other heat shock proteins regu-
lated by S100A6.[25] Recent research showed that S100A6-binding
protein and Siah-1 interacting protein (CacyBP/SIP) interact di-
rectly withHSP90.[26] There are a few studies aboutHSP90 levels
in PE. Although not comparable with this study, Hromoadnikova
et al. found decreased HSP90 mRNA in whole peripheral blood
of mothers with PE. On the other hand, they found a signiﬁcant
upregulation of HSP90 in placental tissue in patients with mild
PE while there was no diﬀerence in severe PE.[27]
The immunoﬂuorescence results of S100A6 and HSP90 (Fig-
ure 2) showed partially colocalization in trophoblast cells. The
numbers of placenta tissue analyzed in this study (n = 5 in each
group) were too small to report information whetherHSP90 was
upregulated in PE. In case of S100A6, we reported previously that
S100A6 was elevated in a larger cohort (n = 138).[5]
Heme oxygenase plays a role in the protective mechanism
against oxidative and nitrosative stress. Ekambaram et al.[28]
showed increased levels of HSP90 in umbilical cord blood RBC
(red blood cells) and decreased heme oxygenase-2 in PE. HSP90
is thought to play a role in this mechanism. Higher hemoglobin
concentrations have been associated with inadequate plasma
volume expansion, which may be part of the preeclamptic
syndrome.[29] An alternative explanation for the higher HSP90
level in PE in the third trimester of pregnancy might be that
patients with PE frequently show hemolysis. In order to inves-
tigate this, we tested the correlation of HSP90 levels in the third
trimester of pregnancy with haptoglobin and lactate dehydroge-
nase concentrations, which were available in the PE group. We
did not ﬁnd correlation betweenHSP90 and these parameters of
hemolysis (data not shown). However, this might have been due
to the small size of this group (n= 9). By unsupervised hierarchi-
cal clustering of themetadata the preeclamptic and control group
were completely separated. S100A6 and HSP90 contributed to
the hierarchical clustering.
Serum levels of S100A6 and HSP90 were measured to our
knowledge for the ﬁrst time in a relatively large group of women
with PE and normotensive controls although for an elaborate sta-
tistical analysis still low in number. Moreover, measuring these
samples cross-sectionally during all trimesters of pregnancy is
unique. Although EU activities in that direction to get access to
larger numbers of PE and control serum samples are ongoing
(the IMPROvED programme, http://www.fp7-improved.eu), the
uniqueness of collecting these samples hampers the ﬁnding of
reliable biomarkers for PE. Another limitation of this study is
that samples were collected in a tertiary hospital setting in which
some patients suﬀered from other chronic diseases. For example,
S100A6 levels were notably high in patients with diabetes melli-
tus and gestational diabetes.[30] Thismay be related to the fact that
the RAGE receptor plays an important role in diabetes. However,
excluding the ﬁve patients with this diagnosis from analysis did
not change the results.
In the last decades, many inventories have been made to ﬁnd
good predictive biomarkers for PE. However, still low predictive
values with markers have been reached, for both single and mul-
tiple protein markers.[31] To get more insight in the pathophysio-
logical process during impaired placentation and PE will lead to
more targeted ways for searching predictivemarkers. We showed
that S100A6 andHSP90 are proteins that need further validation
as candidate biomarkers in dedicated large cohort study initia-
tives for PE as the IMPROvED programme mentioned above.
In conclusion, we developed a PRM method to measure con-
centrations of S100A6 and HSP90 that could play a role during
the pathophysiological process in PE, in a unique set of maternal
serum samples transversally collected in all trimesters of preg-
nancy fromwomen with PE and age-matched normotensive con-
trols.
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